Last reviewed · How we verify
ECADOTRIL
At a glance
| Generic name | ECADOTRIL |
|---|---|
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Diarrhoea
- Laryngitis
- Bronchiolitis
- Dermatitis
Key clinical trials
- Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION) (NA)
- Racecadotril for Organ Injury in Sepsis Patients (PHASE1, PHASE2)
- Safety and Efficacy of Racecadotril in Children With Acute Watery Diarrhea (NA)
- Racecadotril Versus Standard Treatment in Decreasing the Duration of Acute Diarrhoea in Children (PHASE1, PHASE2)
- Bioequivalence Study of Generic Racecadotril 100 mg Capsules Under Fasting Conditions (PHASE1)
- Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea (PHASE3)
- Anti-Secretory Drug in Treatment of Acute Watery Diarrhea (PHASE1)
- Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ECADOTRIL CI brief — competitive landscape report
- ECADOTRIL updates RSS · CI watch RSS